Kazan National Research Technological University

OmniAb Announces Agenda for its Research & Technology Virtual Event

Retrieved on: 
星期二, 十月 31, 2023
Health, Infectious Diseases, Genetics, Health Technology, Pharmaceutical, Biotechnology, Business development, Kazan National Research Technological University, Q&A, Discovery system (bibliographic search), Management

OmniAb, Inc. (Nasdaq: OABI) announces the agenda for its Research & Technology virtual event to be held on Thursday, November 9th beginning at 11:00 a.m. Eastern time.

Key Points: 
  • OmniAb, Inc. (Nasdaq: OABI) announces the agenda for its Research & Technology virtual event to be held on Thursday, November 9th beginning at 11:00 a.m. Eastern time.
  • The two-hour event will include an update on the company’s technology offerings, a review of third quarter financial results, which will be announced earlier that morning, and a Q&A session.
  • The agenda for the event is as follows:
    Business Overview and Updates – Matt Foehr, Chief Executive Officer
    Creating Value for our Partners – Todd Pettingill, Vice President, Business Development and Strategy
    Introducing the OmnidAb™ Technology – Bill Harriman, Ph.D., Sr. Vice President, Antibody Discovery
    Enhancing Discovery with OmniDeep™ – Bob Chen, Ph.D., Sr. Director, Discovery Systems
    The Ion Channel Opportunity – Doug Krafte, Ph.D., Sr. Vice President, Ion Channels/Transporters
    Financial Updates – Kurt Gustafson, Chief Financial Officer
    Interested parties are requested to register in advance by clicking here .
  • The live and archived webcast, along with speaker slides, will be available on the Investors portion of OmniAb’s website.

ShapeTX Announces the Appointment of Adrian W. Briggs, Ph.D. As Chief Technology Officer

Retrieved on: 
星期二, 六月 20, 2023
Max Planck Institute for Medical Research, Nobel Prize, Partnership, Bristol Myers Squibb, RNA, AAV, Doctor of Philosophy, Harvard Medical School, Nobel Prize in Physiology or Medicine, Juno Therapeutics, Entrepreneurship, Kazan National Research Technological University, AI, Max Planck, R, Therapy, Pharmaceutical industry, Medicine, Physiology

SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced the appointment of Adrian W. Briggs, Ph.D. as Chief Technology Officer (CTO).

Key Points: 
  • SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced the appointment of Adrian W. Briggs, Ph.D. as Chief Technology Officer (CTO).
  • Throughout his career, Dr. Briggs has been leading teams to develop disruptive technological innovations in life sciences.
  • AbVitro was acquired by Juno Therapeutics, and shortly after by Bristol Myers Squibb, where Dr. Briggs led technology-focused teams.
  • “Adrian’s leadership and success in using technology to solve intractable problems ensure we remain at the forefront of technological advancements as we guide our promising therapies one step closer to the clinic,” said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX.

Scispot Graduates from Creative Destruction Lab, Setting Stage for Product Expansion and Increased Fundraising

Retrieved on: 
星期二, 六月 13, 2023
Informatics, Kazan National Research Technological University, CDL, Business development, Therapy, Supersessionism, Madrona Venture Group, CXO, Mentorship, Creative, Machine learning, Y Combinator, Pleasure, Artificial intelligence, Growth, Kite Pharma, Regional Municipality of Waterloo, CPO, Nursing, Management

KITCHENER, Ontario, June 13, 2023 /PRNewswire-PRWeb/ -- Scispot, a Y Combinator-backed life science informatics company based in Kitchener-Waterloo and Seattle, recently graduated from the Computational Health Stream of the Creative Destruction Lab (CDL) program in Seattle. The CDL is a highly sought-after program focused on fostering growth in massively scalable, seed-stage science and technology-based companies. In 2022 alone, the CDL received more than 2,200 applications from 87 countries, and out of 650 ventures admitted, only 240 successfully graduated. Among these, just three were chosen to present at the prestigious Supersession in Toronto — Scispot is proud to be among these top three ventures.

Key Points: 
  • The CDL is a highly sought-after program focused on fostering growth in massively scalable, seed-stage science and technology-based companies.
  • In 2022 alone, the CDL received more than 2,200 applications from 87 countries, and out of 650 ventures admitted, only 240 successfully graduated.
  • "Scispot is an essential innovation in our data-driven landscape, ingeniously connecting disparate data and automating workflows within life science companies.
  • Currently supporting therapeutics and industrial bio companies, Scispot has big plans to expand its team and augment its product, positioning the company for explosive growth and fundraising success.

Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets

Retrieved on: 
星期一, 十一月 7, 2022
CEO, Technology, Company, YBG, Animal, Therapy, Humanities, Student, Ministry of Agriculture, Food and Rural Affairs (Ontario), Food, Tissue, GLOBE, Drink, Coenzyme Q10, Human, Hand, Biochemistry, Department, McMaster University, University, ALG, Kazan National Research Technological University, Innovation, Inhalation, Lung, Microbiology, Nutritional science, Engineering, Immune system, Tongue, University of Alberta, MBA, CZO, Faculty, Biopolymer, Water, Pharmaceutical industry, Management, Research

Ceapro demonstrated significantly improved delivery of this notoriously poorly bioavailable bio-active into the tissues vs. the current gold standard in oral CoQ10 supplementation.

Key Points: 
  • Ceapro demonstrated significantly improved delivery of this notoriously poorly bioavailable bio-active into the tissues vs. the current gold standard in oral CoQ10 supplementation.
  • The Ceapro team and board are very motivated by all of our findings and developments as it provides a clearer picture of the untapped potential of the PGX Technology.
  • Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals.
  • The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering.

Ceapro Inc. Present PGX Enabling Technology Case Study at the 13th International Symposium on Supercritical Fluids

Retrieved on: 
星期五, 五月 13, 2022
Department, Material, Microbiology, CZO, Company, Biopolymer, Food, Lecture, Gum arabic, Organic acid, Fluid mechanics, Technology, Starch, Biochemistry, Kazan National Research Technological University, ISSF, Human, International Symposium on Fluorous Technologies, University, Nutritional science, Aerogel, Wound healing, Animal, Innovation, GLOBE, Fine chemical

To date, PGX has generated aerogels with many biopolymers including alginates, pectin, oat beta glucan, gum arabic, corn starch, nanocrystalline cellulose, and composites consisting of yeast beta glucan and alginate.

Key Points: 
  • To date, PGX has generated aerogels with many biopolymers including alginates, pectin, oat beta glucan, gum arabic, corn starch, nanocrystalline cellulose, and composites consisting of yeast beta glucan and alginate.
  • The unique method of the PGX Technology, unlike conventional aerogel formation procedures, does not require many time-consuming and solvent handling steps, such as gelation, cross-linking, and solvent exchange procedures.
  • The PGX Technology is ideally suited for processing challenging high-molecular-weight, water-soluble biopolymers.
  • Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals.

Kent State University Standardizes on Aruba ESP Network to Power Current and Future Academic, Research and Residential Experiences

Retrieved on: 
星期一, 十月 25, 2021
Mobile, Wireless, Technology, Security, Software, Networks, Internet, Hardware, University, Data Management, Education, HPE, Hewlett Packard Enterprise, Research, Technology, Educause, Airheads, Blog, Kazan National Research Technological University, Innovation, APS, CIO, Â, Podiatry, Twitter, AP, LAN, Faculty, Policy, NYSE, Central, Glass, Radio resource location services protocol, Telecommunication, Geist, Multimedia, Attention, IOT, Program, Woolley Edge services, Solution, Western University College of Podiatric Medicine, Wi-Fi, Flexible, NAC, WAN, AI, Student, Medicine, Internet service provider, Video game console, Renewable energy, Tutoring, Mobile phone

Aruba, a Hewlett Packard Enterprise company (NYSE: HPE), today announced that Kent State University , based in Kent, Ohio, is standardizing on an end-to-end Aruba ESP network .

Key Points: 
  • Aruba, a Hewlett Packard Enterprise company (NYSE: HPE), today announced that Kent State University , based in Kent, Ohio, is standardizing on an end-to-end Aruba ESP network .
  • (Photo: Kent State University)
    To power todays academic, research and residential innovations, while meeting the swiftly-changing expectations of its campus communities during the years ahead, Kent State is deploying Arubas wired, wireless, management and security solutions.
  • We needed a reliable, secure high-performance network that could evolve rapidly, explained John Rathje, vice president of IT and CIO at Kent State.
  • With Aruba, we can continuously modernize our network, which helps ensure we can deliver the best possible user experiences across a full spectrum of present and future activities, he added.

Transformational Power Flow Control Technology Unlocks Cross-Border Electricity Capacity in Southeastern Europe

Retrieved on: 
星期四, 十月 21, 2021
Employment Development Department, Efficiency, German Renewable Energy Sources Act, Technology, Research, SAN, Kazan National Research Technological University, Innovation, RES, R&I, IPTO, Green Deal, Face, New European Transmission System, RT, ADMIE, S.A, European environmental research and innovation policy, Maintenance, Software, Primary energy, Environment, Multimedia, DD, ESO, Solution, Department, Renewable energy

SAN FRANCISCO, Oct. 21, 2021 /PRNewswire/ -- A transformational grid enhancing technology, SmartValve, has been successfully commissioned in Greece, marking the second deployment of power flow control technology by IPTO.

Key Points: 
  • SAN FRANCISCO, Oct. 21, 2021 /PRNewswire/ -- A transformational grid enhancing technology, SmartValve, has been successfully commissioned in Greece, marking the second deployment of power flow control technology by IPTO.
  • By intelligently controlling the flows of power across the network, this technology can unlock available cross border interconnection capacity between Greece and Bulgaria.
  • The technology works by pushing power off overloaded lines and pulling power on to underutilized lines; balancing power flows across multiple lines and relieving internal constraints that limit cross-border flows.
  • Mr. Konstantinos Plakas, Research Electrical Engineer of IPTO's Research, Technology & Development Department, said "Studies showed that additional capacity could be made available with the use of this technology".